Bristol Myers Squibb (BMS) has agreed to acquire Karuna Therapeutics for $14 billion, the companies said today, in a deal intended to bolster the buyer’s neurological drug portfolio with Karuna’s ...
Covington, La. based marine engineering and services firm Baker Marine Solutions (BMS) has unveiled a new pipe mill barge concept design targeting uptake in the U.S. offshore wind industry. BMS ...
Bristol Myers Squibb (BMS) has revealed clinical data for two pipeline candidates in multiple myeloma (MM) at the European ...
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced updated results from three key programs within its broad multiple myeloma research pipeline, highlighting its diverse ...
California manufacturer Cellares—which touts its ability to produce cell and gene therapies faster, cheaper and at a larger scale—has partnered with Bristol Myers Squibb. (Cellares) As he talks about ...
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) is today holding a Research and Development (R&D) Day in New York to discuss the company’s R&D strategy and capabilities and to ...
Recent price target moves for Bristol-Myers Squibb, including adjustments to US$70, US$75 and US$60, sit against only a very small shift in one fair value estimate from US$63.04 to US$62.96. These ...
Bristol Myers Squibb Co. (BMS) has terminated its $1.3 billion-plus deal for Agenus Inc.’s anti-TIGIT bispecific antibody AGEN-1777 as part of a promised belt-tightening. In May 2021, BMS paid Agenus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results